Dashboard
Manage Tickers

LXRXLEXICON PHARMACEUTICALS, INC.

Nasdaq lexpharma.com


$ 1.69 $ -0.32 (-16.09 %)    

Friday, 02-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 447.95 $ -10.91 (-2.37 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 1.695
$ 1.69 x 1,100
-- x --
-- - --
$ 0.92 - $ 3.73
5,564,609
na
417.37M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-02-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-25-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-03-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 10-30-2020 09-30-2020 10-Q
17 07-29-2020 06-30-2020 10-Q
18 04-27-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 07-30-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-01-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-06-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5-analysts-have-this-to-say-about-lexicon-pharmaceuticals
5 Analysts Have This To Say About Lexicon ...
08/02/2024 18:09:05

hc-wainwright--co-reiterates-buy-on-lexicon-pharmaceuticals-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Lexi...
08/02/2024 12:22:17

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...

why-doordash-shares-are-trading-higher-by-10-here-are-20-stocks-moving-premarket
Why DoorDash Shares Are Trading Higher By ...
08/02/2024 12:15:41

intel-reports-weak-results-joins-amazon-opendoor-technologies-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Intel Reports Weak Results, Joins Amazon, ...
08/02/2024 10:01:13

lexicon-pharmaceuticals-q2-2024-gaap-eps-017-beats-019-estimate-sales-1647m-miss-2831m-estimate
Lexicon Pharmaceuticals Q2 2024 GAAP EPS $...
08/01/2024 20:02:29

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate ...

hc-wainwright--co-reiterates-buy-on-lexicon-pharmaceuticals-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Lexi...
07/16/2024 17:30:13

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...

lexicon-pharmaceuticals-receives-dec-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission
Lexicon Pharmaceuticals Receives Dec. 20, ...
07/16/2024 12:06:18

lexicon-pharmaceuticals-announces-new-analysis-of-phase-3-soloist-whf-trial-shows-positive-economic-impact-on-hospitals-using-alternative-payment-models-published-in-journal-of-managed-care--specialty-pharmacy-inpefa-for-heart-failure-and-comorbid-diabetes-provides-significant-financial-benefits-for-provider-health-systems
Lexicon Pharmaceuticals Announces New Anal...
07/15/2024 12:07:35

lexicon-appoints-mike-exton-as-new-chief-executive-officer-and-director-succeeding-lonnel-coats-who-as-previously-announced-retired-effective-july-7-2024
Lexicon Appoints Mike Exton As New Chief E...
07/08/2024 13:21:07

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D....

hc-wainwright--co-reiterates-buy-on-lexicon-pharmaceuticals-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Lexi...
06/24/2024 10:36:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...

hc-wainwright--co-reiterates-buy-on-lexicon-pharmaceuticals-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Lexi...
06/21/2024 14:15:03

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...

lexicon-pharmaceuticals-resubmits-nda-for-sotagliflozin-as-adjunct-to-insulin-therapy-for-glycemic-control-in-type-1-diabetes-and-chronic-kidney-disease-expects-six-month-review-and-potential-early-2025-launch
Lexicon Pharmaceuticals Resubmits NDA For ...
06/21/2024 12:02:55

reported-wednesday-lexicon-published-data-from-relief-dpn-1-phase-2-study-of-lx9211-in-diabetes-care
Reported Wednesday, Lexicon Published Data...
06/20/2024 09:19:54

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits...

lexicon-pharmaceuticals-presents-analysis-of-inpefa-cost-effectiveness-published-in-jacc-heart-failure-the-peer-reviewed-journal-of-the-american-college-of-cardiology
Lexicon Pharmaceuticals Presents Analysis ...
06/18/2024 12:20:03

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another s...

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

aarons-mirum-pharmaceuticals-primo-water-and-other-big-stocks-moving-higher-on-monday
Aaron's, Mirum Pharmaceuticals, Primo Wate...
06/17/2024 13:59:35

hc-wainwright--co-initiates-coverage-on-lexicon-pharmaceuticals-with-buy-rating-announces-price-target-of-10
HC Wainwright & Co. Initiates Coverage On ...
06/17/2024 10:21:08

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy rati...

lexicon-pharmaceuticals-presents-findings-on-the-burdens-of-diabetic-peripheral-neuropathic-pain-among-3-sponsored-presentations-at-the-84th-scientific-sessions-of-the-american-diabetes-association
Lexicon Pharmaceuticals Presents Findings ...
06/14/2024 12:15:36

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that three poster presentations will be delivered during the 84th S...

needham-reiterates-hold-on-lexicon-pharmaceuticals
Needham Reiterates Hold on Lexicon Pharmac...
05/03/2024 12:25:01

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Hold.

lexicon-pharmaceuticals-q1-2024-gaap-eps-020-inline-sales-1130m-miss-1401m-estimate
Lexicon Pharmaceuticals Q1 2024 GAAP EPS $...
05/02/2024 20:07:55

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)